EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSLACG00000005644
Gene Symbol: KCNQ2
2 Cross references
248 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSLACG00000004077
Gene Symbol: KCNQ5
3 Cross references
278 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSLACG00000018457
Gene Symbol: KCND3
1 Cross references
258 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSLACG00000018405
Gene Symbol: KCND3
2 Cross references
258 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSLACG00000011253
Gene Symbol: PSEN1
2 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSLACG00000016973
Gene Symbol: PSEN2
2 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSLACG00000008935
Gene Symbol: PSENEN
4 Cross references
183 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSLACG00000013150
Gene Symbol: PGR
4 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSLACG00000000282
Gene Symbol: PTGDR
2 Cross references
118 Possible Orthologues:

Prostaglandin E Receptor 1

Ensembl ID : ENSLACG00000016145
Gene Symbol: PTGER1
4 Cross references
235 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSLACG00000022651
Gene Symbol: PTGER2
4 Cross references
241 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSLACG00000003866
Gene Symbol: PTGER3
4 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).